NKX2-5 and esophageal squamous cell carcinoma: The concurrent inhibition of UHRF1 and DNMTs significantly enhanced therapeutic responsiveness, thus revealing a promising therapeutic strategy for patients with ESCC exhibiting NKX2‐5/LHX1/UHRF1 overexpression (Figure 6G).